BGF World Healthscience Fund USD
Benefit from strong growth in healthcare
BGF World Healthscience Fund is a sub-fund of the SICAV/BEVEK investment fund under Luxembourg law BlackRock Global Funds (BGF). The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund’s assets. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. For the purpose of managing currency exposure, the investment adviser (IA) may use investment techniques (which may include the use of financial derivative instruments (FDIs)) to protect the value of the Fund, in whole or part, or enable the Fund to profit from changes in currency exchange rates against the base currency of the Fund. FDIs are investments the prices of which are based on one or more underlying assets. The IA has discretion to select the Fund's investments and in doing so may take into consideration the MSCI World Healthcare Index. Recommendation: This Fund may not be appropriate for short-term investment. Your shares will be denominated in US Dollar, the Fund's base currency. You can buy and sell your shares daily.
Before you invest in BGF World Healthscience Fund, your are advised to read carefully the following documents:
- The Key Investor Information Document or KIID (PDF)
- The prospectus (PDF)
- The last periodic report (PDF)
These documents are available for free in your ING-branch or on this website. These documents are available in English, Dutch or French.
The fund BGF World Healthscience Fund is not an ING fund.
Historical records – Actuarial Yield – Capitalization share
|Valid on 30/09/2015||Return (%)|
|id||Fund manager||Fund||Fund Type||Morningstar™||inventaris waarde||Currency||after 1 year||after 3 years||after 5 years||after 10 years||since inception||Launch date||Year-to-date||url||award||Return (%)|
|LU0122379950||BlackRock||BlackRock Glb World Healthscience Fund||Equity||4||32,8||US Dollar||4,49||19,92||16,91||9,64||8,55||2001/04/06||-2,81||www.ing.be/en/retail/investments/investment-funds/BGF-world-healthscience-fund?||0|
Source : Morningstar Direct ™
Actuarial gain expressed on an annual basis in the currency of the relevant UCITS over 1 year, 3 years, 5 years,10 years and since inception. It relates to end-of-month returns based on historical data. The returns shown are valid for the capitalised parts of the UCITS and take no account of entry fees and potential taxes. Past performance is no guarantee of future performance and can be misleading. The value of shares in the fund and income received from it can go down as well as up, and investors may not get back the full amount invested. All performance data shown is in euro, include reinvested dividends and are net of management fees. Sales charges and other commissions, taxes and other relevant costs paid by the investor are not included in the calculations.
Fund launch date: April 2001
Class Launch date: April 2001
Reference currency:The reference currency is the American Dollar. The yield in euro could be positively or negatively influenced by currency fluctuations.
For an investor seeking:
Wanting to potentially grow their long-term wealth by investing in a diversified portfolio of health sciences related stocks, in order to benefit from the sector’s secular growth drivers leading to favourable fundamentals in select healthcare companies across the globe.
The main risks for the Sub-Fund are :
- Investment risk Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political or regulatory events.
- Stock market movements: The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events.
- Currency risk : Active management of currency exposure through derivatives may make the Fund more sensitive to changes in foreign exchange rates. If the currency exposures against which the Fund is hedged appreciates investors may not benefit from such appreciation
- Counterparty risk: The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss.
The occurrence of any of these risks may have an impact on the net asset value of your portfolio.
Net Asset Value
The net asset value is calculated in Belgium each bank working day. The net asset value is published every public banking business day in Belgium in the financial press, as well as on the BeAMA website (http://www.beama.be/en/nav). It is also available at the Management Company’s registered address and over the counter from your financial services provider.
A swing price may be applied. Swing pricing aims to reduce the dilution effect brought about when significant operations within a sub- fund compel its manager to buy or sell its underlying assets. These transactions give rise to transaction fees and taxes that have an effect on the fund’s value, as well as on all its investors. Where swing pricing is applied, the sub-fund’s net asset value is adjusted by a particular amount when the capital flow exceeds a certain threshold (the swing factor). This amount is designed to offset expected transaction fees resulting from the difference between incoming and outgoing capital. Swing pricing is only used on rare occasions, if at all.
Please refer to the BGF World Healthscience Fund USD prospectus (PDF) for additional information.
Minimum investment: 1 part
- Entry charge (applicable by ING Belgium): 3%
- Exit charge: 0%
Ongoing charges taken from the Sub-Fund over a year: 1.81% of which (maximum) 1,50 % of management fees.
Custody fee: 0%/ annum
For other charges that might be paid by the investor, we refer to the prospectus.
- Stock exchange tax (applicable to redemptions only):
- Capitalization share: 1,32% (max 4000 EUR)
- Distribution share: none
- Withholding tax on dividends:
- Capitalization share: none
- Distribution share: 30 %
- Withholding tax in case of redemption:
- Sub-fund permitted to invest more than 25% of assets in debt securities: no
- Sub-fund actually more than 25% invested in debt securities: no
- Withholding tax ( 30 % depending on the investor’s particular tax situation): not applicable
*Tax treaty based on the current legislation
Dividends received from distributing shares are subject to the Belgian withholding tax of 30 %. The Belgian withholding tax applicable to interests included in the repurchase price of accumulating and distributing shares investing more than 25% of their assets in any kind of debts amounts to 30 %.
This tax system applies to Retail customers – private individuals resident in Belgium. Taxation depends on the individual situation of each customer and may change in the future.
Identity of de financial agent
Financial Service Belgium : J.P. Morgan Chase Bank, Boulevard du Roi Albert II 1, B-1210 Bruxelles
Complaints can be lodged with ING – Customer Service – Cours Saint Michel, 60 – 1040 Brussels. If no settlement can be reached in this way, please contact the Banks - Credit - Investments Mediation Service (www.ombudsfin.be).